Rheumatoid Arthritis (RA) - Market Insights,
Epidemiology and Market Size Forecast-2020” Reports provides an overview of the
disease and global market size of the Rheumatoid Arthritis (RA) for the United
States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes
global historical and forecasted epidemiological data for the diagnosed incident
cases of Rheumatoid Arthritis (RA) from 2010-2020.Rheumatoid arthritis is an
autoimmune disease in which the body’s immune system – which normally protects
its health by attacking foreign substances like bacteria and viruses –
mistakenly attacks the joints. RA affects between 0.5 and 1% of adults in the
developed world with between 5 and 50 per 100,000 people newly developing the
condition each year. RA reduces lifespan on average from three to twelve years.
It is unknown how these agents compare to the current biologics because there
are no head-to-head trials to date. Most studies are conducted on patients who
have already failed current therapy, suggesting that the likely niche for these
newer pipeline agents may be for RA that is more severe.
Scope
- Report covers the disease overview including etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2010-2020.
- It also provides Market size of Rheumatoid Arthritis (RA) for United States, EU5 and Japan from 2010 and forecasted Market size to 2020
Spanning over 70 pages “Rheumatoid
Arthritis (RA) - Market Insights, Epidemiology and Market Size Forecast - 2020”
report
covers Disease overview, Pathophysiology, Symptoms of disease, Appendix, Report
Methodology
For
more information Visit at: http://mrr.cm/Jkh
Find all Pharma and Healthcare
Report: http://www.marketresearchreports.com/pharma-healthcare
No comments:
Post a Comment
Note: only a member of this blog may post a comment.